Your browser doesn't support javascript.
loading
Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease.
de Savornin Lohman, Elise A J; van der Geest, Lydia G; de Bitter, Tessa J J; Nagtegaal, Iris D; van Laarhoven, Cornelis J H M; van den Boezem, Peter; van der Post, Chella S; de Reuver, Philip R.
Afiliación
  • de Savornin Lohman EAJ; Department of Surgery, Route 618, Radboudumc, Nijmegen, The Netherlands.
  • van der Geest LG; Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands.
  • de Bitter TJJ; Department of Pathology, Radboudumc, Nijmegen, The Netherlands.
  • Nagtegaal ID; Department of Pathology, Radboudumc, Nijmegen, The Netherlands.
  • van Laarhoven CJHM; Department of Surgery, Route 618, Radboudumc, Nijmegen, The Netherlands.
  • van den Boezem P; Department of Surgery, Route 618, Radboudumc, Nijmegen, The Netherlands.
  • van der Post CS; Department of Pathology, Radboudumc, Nijmegen, The Netherlands.
  • de Reuver PR; Department of Surgery, Route 618, Radboudumc, Nijmegen, The Netherlands. philip.dereuver@radboudumc.nl.
Ann Surg Oncol ; 27(4): 1132-1142, 2020 Apr.
Article en En | MEDLINE | ID: mdl-31741109
ABSTRACT

BACKGROUND:

Re-resection for incidental gallbladder cancer (iGBC) is associated with improved survival but little is known about residual disease (RD) and prognostic factors. In this study, survival after re-resection, RD, and prognostic factors are analyzed.

METHODS:

Patients with iGBC were identified from the Netherlands Cancer Registry, and pathology reports of re-resected patients were reviewed. Survival and prognostic factors were analyzed.

RESULTS:

Overall, 463 patients were included; 24% (n = 110) underwent re-resection after a median interval of 66 days. RD was present in 35% of patients and was most frequently found in the lymph nodes (23%). R0 resection was achieved in 93 patients (92%). Median overall survival (OS) of patients without re-resection was 13.7 (95% confidence interval [CI] 11.6-15.6), compared with 52.6 months (95% CI 36.3-68.8) in re-resected patients (p < 0.001). After re-resection, median OS was superior in patients without RD versus patients with RD (not reached vs. 23.1 months; p < 0.001). In patients who underwent re-resection, RD in the liver (hazard ratio [HR] 5.54; p < 0.001) and lymph nodes (HR 2.35; p = 0.005) were the only significant prognostic factors in multivariable analysis. Predictive factors for the presence of RD were pT3 stage (HR 25.3; p = 0.003) and pN1 stage (HR 23.0; p = 0.022).

CONCLUSION:

Re-resection for iGBC is associated with improved survival but remains infrequently used and is often performed after the optimal timing interval. RD is the only significant prognostic factor for survival after re-resection and can be predicted by pT and pN stages.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vesícula Biliar Tipo de estudio: Diagnostic_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vesícula Biliar Tipo de estudio: Diagnostic_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Ann Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos